(5R-cis)-Toluene-4-sulfonic acid 5-(2,4-difluorophenyl)-5-(1H-1,2,4-triazol-1-yl)methyltetrahydrofuran-3-ylmethyl ester

DRUG INTERMEDIATES

Product Details

CAT No.# CS-O-31365
Category Drug Intermediates
CAS 149809-43-8
Molecular Weight 449.47
Molecular Formula C21H21F2N3O4S
Stock Status: In-Stock
Purity: >98%
Synonyms: (5R-cis)-Toluene-4-sulfonic acid 5-(2,4-difluorophenyl)-5-(1H-1,2,4-triazol-1-yl)methyltetrahydrofuran-3-ylmethyl ester; (3S,5R)-5-(2,4-Difluorophenyl)-5-[(1H-1,2,4-triazol-1-yl)methyl]oxolan-3-ylmethyl p-Toluenesulfonate;
Shipping: Free Shipping for worldwide on order above 2000 USD , Extra charges for Dry ice shipment 80$*
COA / MSDS:    View COA    MSDS
The balance used are calibrated with weights traceable to National Standards NIST for accuracy
Related Results for '(5R-cis)-Toluene-4-sulfonic acid 5-(2,4-difluorophenyl)-5-(1H-1,2,4-triazol-1-yl)methyltetrahydrofuran-3-ylmethyl ester'

- API Standards of Posaconazole
- Stable Isotopes of Posaconazole
- Metabolites of Posaconazole
- Impurities of Posaconazole
- Glucuronides of Posaconazole
- Intermediates of Posaconazole

PEOPLE ALSO SEARCHED FOR: 1. propan-2-yl-5-hydroxy-2-methyl-2-4-(3-nitrophenyl)-6-oxo-1,4,5,5-tetraahydropyridine-3-carboxylate
2. ([13C6]Leu5)-Ghrelin (human) (H-7252.1000)
3. Benidipine D7
4. Lauroside D
5. Triazolam 13C D3
6. Icatibant impurity 1
7. BISPHENOL AF (RING-13C12)
8. 0.1% TFA in Water ULC-MS
9. Metamizole EP Impurity C HCl
10. Silodosin Metabolite D4
11. Brivaracetam Carboxylic acid metabolite [UCB 42145]
12. Terbuthylazine D5
13. tibolone (848)
14. (Z)-Dimethylvinphos
15. Silodosin Metabolite
16. 2-Phenoxymethanesulfonanilide
17. Nimesulide EP Impurity A
18. Acetone HPLC
19. Nandrolone Decanoate EP impurity F
20. N-(4-Bromophenyl)-3-methyl-N-(m-tolyl)aniline


Smileys:
FC1=C(C=CC(F)=C1)[C@]2(C[C@H](CO[S](=O)(C3=CC=C(C)C=C3)=O)CO2)CN4C=NC=N4



This page contains information about (5R-cis)-Toluene-4-sulfonic acid 5-(2,4-difluorophenyl)-5-(1H-1,2,4-triazol-1-yl)methyltetrahydrofuran-3-ylmethyl ester Cas 149809-43-8 and its Drug Intermediates.
"Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk."